ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 224.2 DKK 0.09%
Market Cap: 45.4B DKK

ALK-Abello A/S
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ALK-Abello A/S
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
ALK-Abello A/S
CSE:ALK B
Stock-Based Compensation
kr52m
CAGR 3-Years
12%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Stock-Based Compensation
kr2.6B
CAGR 3-Years
29%
CAGR 5-Years
35%
CAGR 10-Years
29%
H Lundbeck A/S
CSE:HLUN A
Stock-Based Compensation
kr37m
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ALK-Abello A/S
Glance View

Market Cap
49.7B DKK
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

ALK B Intrinsic Value
HIDDEN
Show

See Also

What is ALK-Abello A/S's Stock-Based Compensation?
Stock-Based Compensation
52m DKK

Based on the financial report for Sep 30, 2025, ALK-Abello A/S's Stock-Based Compensation amounts to 52m DKK.

What is ALK-Abello A/S's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
5%

Over the last year, the Stock-Based Compensation growth was 0%. The average annual Stock-Based Compensation growth rates for ALK-Abello A/S have been 12% over the past three years , 5% over the past five years .

Back to Top